Skip to content
10-Q

Quarterly Report

Seres Therapeutics, Inc. MCRB

0000950170-25-103611

← back to feed
Filed
Aug 6, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Aug 1, 2025 8.75M sh
Shares Diluted Q2 2025 · Jun 30, 2025 8.74M sh
Shares Diluted Q2 2025 · Jun 30, 2025 8.73M sh
Shares Diluted restated Q2 2025 · Jun 30, 2024 7.58M sh
Shares Diluted restated Q2 2025 · Jun 30, 2024 7.44M sh
Capex Q2 2025 · Jun 30, 2025 $215K
Capex Q2 2025 · Jun 30, 2024 $161K
Operating Cash Flow Q2 2025 · Jun 30, 2025 $13.62M
Operating Cash Flow Q2 2025 · Jun 30, 2024 −$75.05M
Cash And Equivalents Q2 2025 · Jun 30, 2025 $45.38M
Cash And Equivalents Q2 2025 · Dec 31, 2024 $30.79M
Stockholders Equity Q2 2025 · Jun 30, 2025 $32.95M
Stockholders Equity Q2 2025 · Mar 31, 2025 $50.47M
Stockholders Equity Q2 2025 · Dec 31, 2024 $13.78M
Stockholders Equity Q2 2025 · Jun 30, 2024 −$87.07M
Stockholders Equity Q2 2025 · Mar 31, 2024 −$59.74M
Stockholders Equity Q2 2025 · Dec 31, 2023 −$44.86M
Current Liabilities Q2 2025 · Jun 30, 2025 $30.94M
Current Liabilities Q2 2025 · Dec 31, 2024 $41.22M
Total Liabilities Q2 2025 · Jun 30, 2025 $110.85M
Total Liabilities Q2 2025 · Dec 31, 2024 $126.03M
Current Assets Q2 2025 · Jun 30, 2025 $48.69M
Current Assets Q2 2025 · Dec 31, 2024 $38.67M
Total Assets Q2 2025 · Jun 30, 2025 $143.8M
Total Assets Q2 2025 · Dec 31, 2024 $139.81M
Eps Diluted Q2 2025 · Jun 30, 2025 −$2.27
Eps Diluted Q2 2025 · Jun 30, 2025 $1.47
Eps Diluted restated Q2 2025 · Jun 30, 2024 −$4.34
Eps Diluted restated Q2 2025 · Jun 30, 2024 −$9.81
Eps Basic Q2 2025 · Jun 30, 2025 −$2.27
Eps Basic Q2 2025 · Jun 30, 2025 $1.47
Eps Basic restated Q2 2025 · Jun 30, 2024 −$4.34
Eps Basic restated Q2 2025 · Jun 30, 2024 −$9.81
Sga Expense Q2 2025 · Jun 30, 2025 $10.25M
Sga Expense Q2 2025 · Jun 30, 2025 $22.14M
Sga Expense restated Q2 2025 · Jun 30, 2024 $13.07M
Sga Expense restated Q2 2025 · Jun 30, 2024 $28.01M
Rd Expense Q2 2025 · Jun 30, 2025 $12.94M
Rd Expense Q2 2025 · Jun 30, 2025 $24.76M
Rd Expense restated Q2 2025 · Jun 30, 2024 $15.81M
Rd Expense restated Q2 2025 · Jun 30, 2024 $35.3M
Net Income Q2 2025 · Jun 30, 2025 −$19.86M
Net Income Q2 2025 · Jun 30, 2025 $12.83M
Net Income Q2 2025 · Mar 31, 2025 $32.68M
Net Income Q2 2025 · Jun 30, 2024 −$32.87M
Net Income Q2 2025 · Jun 30, 2024 −$73M
Net Income Q2 2025 · Mar 31, 2024 −$40.13M
Operating Income Q2 2025 · Jun 30, 2025 −$24.88M
Operating Income Q2 2025 · Jun 30, 2025 −$52.12M
Operating Income restated Q2 2025 · Jun 30, 2024 −$28.87M
Operating Income restated Q2 2025 · Jun 30, 2024 −$63.31M